Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | KLK1 | P06870 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25525565 | 0.89 | MAPT (0.49) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525568 | 0.84 | LMNA (0.51) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525587 | 0.84 | MAPT (0.45) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525574 | 0.81 | ALDH1A1 (0.49) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525572 | 0.81 | MAPT (0.48) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525570 | 0.78 | MAPT (0.46) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525569 | 0.76 | TP53 (0.42) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525584 | 0.75 | MAPT (0.42) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525580 | 0.73 | TP53 (0.46) | MAPTTP53LMNABRD4BRD2 | |
| SCHEMBL25525591 | 0.72 | BRD4 (0.57) | MAPTLMNABRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | MAPT 1416/4885TP53 4835/4885LMNA 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.